914950-09-7 Usage
General Description
2-chloro-6-ethynylpyridine is a chemical compound that belongs to the class of pyridine derivatives. It is a highly reactive compound that is used in the synthesis of various other organic compounds, particularly in the pharmaceutical and agrochemical industries. 2-chloro-6-ethynylpyridine is known for its unique chemical properties, including its ability to undergo various chemical reactions such as nucleophilic substitution and cross-coupling reactions. It is also used as a building block in the synthesis of more complex organic molecules. However, due to its reactive nature and potential toxicity, proper handling and safety precautions are necessary when working with 2-chloro-6-ethynylpyridine.
Check Digit Verification of cas no
The CAS Registry Mumber 914950-09-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,4,9,5 and 0 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 914950-09:
(8*9)+(7*1)+(6*4)+(5*9)+(4*5)+(3*0)+(2*0)+(1*9)=177
177 % 10 = 7
So 914950-09-7 is a valid CAS Registry Number.
914950-09-7Relevant articles and documents
Modular, Concise, and Efficient Synthesis of Highly Functionalized 5-Fluoropyridazines by a [2 + 1]/[3 + 2]-Cycloaddition Sequence
Tran, Ga?l,Gomez Pardo, Domingo,Tsuchiya, Tomoki,Hillebrand, Stefan,Vors, Jean-Pierre,Cossy, Janine
supporting information, p. 3414 - 3417 (2015/07/28)
An easy access to 5-fluoropyridazines by a [2 + 1]/[3 + 2]-cycloaddition sequence between terminal alkynes, a difluorocarbene, and a diazo compound is reported. This approach does not necessitate the isolation of any intermediates, and a wide range of novel 5-fluoropyridazines was synthesized from readily available starting materials. Additionally, these compounds were used as a platform to access novel and highly diversified pyridazines.
Pyrazole derivatives as jak inhibitors
-
Paragraph 0122, (2013/03/26)
New pyrazole derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
